Clinical Study Results
Summary cover?
1. Study Name
Title of the Study: A phase 2, multicenter, randomized, double-blind,
placebo-controlled, parallel-group study to evaluate the
efficacy and safety of apremilast (CC-10004) in Japanese
subjects with palmoplantar pustulosis
Brief Title: Efficacy and safety phase 2 study of apremilast in Japanese
subjects with palmoplantar pustulosis
Protocol Number: CC-10004-PPP-001 (20200055)
EU Trial Number: Not applicable
Other Identifiers: NCT04057937
Date of This 14 April 2022
Summary:
What does this summary cover?
This summary shows the main results from one clinical study. The results are only
for this study. Other studies may find different results. Researchers and health
authorities look at the results of many studies to decide which medicines work best
and are safest for patients.
Amgen has committed to make research results available to the public. This
summary has been provided as part of that commitment and should not be used for
any other purpose. It should not be considered to make a claim for any product or to
guide treatment decisions.